RXST FINANCIAL STATEMENTS

Rxsight Inc — balance sheet, income statement and cash flow trends

RXSTRxsight Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Devices

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue127.5 M $-19.5%

Gross Profit98.2 M $-7.9%

Operating Income-55.3 M $—

EBITDA-43.2 M $—

Net Income-46.6 M $—

Peer Comparison· Medical Devices

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
RXST	-19.5%	77.0%	-33.9%	-36.6%
SN	—	68.0%	25.6%	10.1%
ONCSM	39.1%	48.4%	30.6%	6.3%
MEDTR	6.5%	30.9%	9.4%	0.2%
ANGEN	11.7%	58.8%	9.8%	-45.0%
4DX	-26.0%	-396.6%	-818.8%	-3,684.6%
Industry median	7.4%	58.9%	5.2%	-5.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
RXST	-19.5%	77.0%	-33.9%	-36.6%
INFU	3.5%	56.7%	18.2%	5.6%
QTRX	8.2%	44.1%	-58.4%	-71.9%
QSI	-46.2%	40.0%	-4,942.7%	-5,605.9%
TMCI	-1.7%	79.7%	-22.3%	-29.4%
SGHT	1.8%	86.2%	-39.8%	-46.8%
Industry median	7.4%	58.9%	5.2%	-5.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity267.3 M $88%
Current Liabilities27.4 M $9%
Long-term Liabilities9.3 M $3%

Key Figures

YoY change

Total Assets304 M $-2.9%

Total Liabilities36.7 M $+8.8%

Total Equity267.3 M $-4.3%

Cash & ST Investments217.9 M $-5.0%

Total Debt10.8 M $-10.1%

Net Debt-6.7 M $—

Peer Comparison· Medical Devices

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
RXST	10.20	4.1%	4.79	87.9%
SN	2.57	62.9%	1.72	50.6%
ONCSM	2.25	35.0%	0.42	56.4%
MEDTR	3.58	1.0%	-1.64	83.0%
ANGEN	2.31	28.1%	4.71	67.2%
4DX	6.57	-22.6%	0.71	-20.4%
Industry median	3.28	44.7%	0.82	49.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
RXST	10.20	4.1%	4.79	87.9%
INFU	2.14	38.8%	0.80	59.5%
QTRX	3.72	12.5%	0.76	76.9%
QSI	12.60	1.8%	1.35	94.1%
TMCI	3.58	17.6%	0.83	41.9%
SGHT	5.86	77.5%	1.36	49.1%
Industry median	3.28	44.7%	0.82	49.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-17.6 M $—

Capital Expenditures4 M $-0.8%

Free Cash Flow-21.6 M $—

Dividends Paid——

Peer Comparison· Medical Devices

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
RXST	-13.8%	-16.9%	3.1%	37.7%
SN	20.8%	13.8%	7.0%	205.6%
ONCSM	6.2%	-5.5%	12.0%	99.3%
MEDTR	21.1%	27.9%	6.6%	10,700.8%
ANGEN	40.2%	-21.2%	61.5%	-89.3%
4DX	-761.6%	-530.7%	3.7%	20.7%
Industry median	7.2%	1.5%	4.1%	76.6%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
RXST	-13.8%	-16.9%	3.1%	37.7%
INFU	16.6%	11.6%	5.0%	298.3%
QTRX	-56.2%	-57.2%	1.1%	78.2%
QSI	-5,086.4%	-5,166.8%	82.2%	90.7%
TMCI	-6.2%	-12.5%	6.3%	21.2%
SGHT	-31.6%	-31.9%	0.7%	67.4%
Industry median	7.2%	1.5%	4.1%	76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RXST

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.